Moreover, TGF-β and IL-10 can impair the cross-presentation of DCs to T cells in multiple cancers and it has been shown that the suppression of TGF-β and IL-10 receptors on self-differentiated DCs enhanced the activation of effector T cells against CCA tumor cells [74]. The gene discussed is IL10; the disease is neoplasm.